Phaseline

Targets › LILRB2

LILRB2 (Leukocyte immunoglobulin-like receptor subfamily B member 2): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Feb 2027.

Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles. (UniProt, Q8N423)

Open in Phaseline: the race on LILRB2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
OncoResponseOR502
anti-LILRB2 monoclonal antibody
LILRB2Phase 1CancerFeb 2027
SparX Biotech(Jiangsu) Co., Ltd.SPX-303
Bispecific antibody targeting LILRB2 and PD-L1
LILRB2, PDCD274Phase 1Solid TumorSep 2027

Conditions

Solid Tumor (1) Cancer (1)

Modalities

antibody (1), mixed (1)

Companies

SparX Biotech(Jiangsu) Co., Ltd. (1) OncoResponse (1)

Related targets

PDCD274 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.